Analysts Offer Predictions for AKBA FY2029 Earnings

Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) - Investment analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Akebia Therapeutics in a report released on Tuesday, January 14th. HC Wainwright analyst E. Arce forecasts that the biopharmaceutical company will earn $2.17 per share for the year. HC Wainwright has a "Buy" rating and a $7.50 price objective on the stock. The consensus estimate for Akebia Therapeutics' current full-year earnings is ($0.26) per share.

Separately, StockNews.com cut Akebia Therapeutics from a "hold" rating to a "sell" rating in a report on Wednesday.

Akebia Therapeutics Price Performance

Shares of AKBA stock traded up $0.14 during trading hours on Thursday, reaching $2.07. 6,508,283 shares of the company's stock were exchanged, compared to its average volume of 2,497,784. The company has a market cap of $451.63 million, a P/E ratio of -9.00 and a beta of 0.72. The company's 50 day moving average is $1.91 and its two-hundred day moving average is $1.57. Akebia Therapeutics has a 1 year low of $0.80 and a 1 year high of $2.48.

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.06). The firm had revenue of $37.43 million during the quarter, compared to analyst estimates of $45.66 million. During the same period last year, the business posted ($0.08) earnings per share.

Institutional Investors Weigh In On Akebia Therapeutics

A number of large investors have recently bought and sold shares of AKBA. State Street Corp grew its holdings in Akebia Therapeutics by 24.9% during the 3rd quarter. State Street Corp now owns 3,430,527 shares of the biopharmaceutical company's stock valued at $4,528,000 after buying an additional 683,287 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Akebia Therapeutics by 3,122.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 604,551 shares of the biopharmaceutical company's stock valued at $617,000 after buying an additional 585,789 shares during the last quarter. Wellington Management Group LLP acquired a new stake in Akebia Therapeutics during the 3rd quarter valued at $534,000. Renaissance Technologies LLC grew its holdings in Akebia Therapeutics by 7.2% during the 2nd quarter. Renaissance Technologies LLC now owns 3,914,800 shares of the biopharmaceutical company's stock valued at $3,993,000 after buying an additional 262,700 shares during the last quarter. Finally, Rhumbline Advisers grew its holdings in Akebia Therapeutics by 4,915.4% during the 2nd quarter. Rhumbline Advisers now owns 247,060 shares of the biopharmaceutical company's stock valued at $252,000 after buying an additional 242,134 shares during the last quarter. Institutional investors and hedge funds own 33.92% of the company's stock.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.